Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

Neurology. 2002 Jan 22;58(2):169-78. doi: 10.1212/wnl.58.2.169.
No abstract available

Publication types

  • Guideline
  • Practice Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Clinical Trials as Topic
  • Evidence-Based Medicine
  • Glatiramer Acetate
  • Glucocorticoids / therapeutic use*
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunosuppressive Agents / therapeutic use*
  • Interferon-beta / immunology
  • Interferon-beta / therapeutic use*
  • Mitoxantrone / therapeutic use
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology
  • Multiple Sclerosis / physiopathology
  • Multiple Sclerosis / therapy*
  • Peptides / therapeutic use
  • Plasma Exchange
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Immunoglobulins, Intravenous
  • Immunosuppressive Agents
  • Peptides
  • Glatiramer Acetate
  • Interferon-beta
  • Mitoxantrone